Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 57-Week, Multicenter, Active-treatment, Open-label Extension Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizures

NCT04686786 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04686786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04686786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 57-Week, Multicenter, Active-treatment, Open-label Extension Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizures
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Terminated
Start date
December 8, 2020
Completion date
December 5, 2024
Enrollment
105 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

seizures